[{"orgOrder":0,"company":"XPhyto","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Cannabigerol","moa":"CB1 receptor","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"XPhyto","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Sublingual","sponsorNew":"XPhyto \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"XPhyto \/ Not Applicable"},{"orgOrder":0,"company":"180 Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Cannabigerol","moa":"","graph1":"Neurology","graph2":"Preclinical","graph3":"180 Life Sciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"180 Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"180 Life Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Oregon State University","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Cannabigerol","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Oregon State University","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Oregon State University \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Oregon State University \/ Not Applicable"},{"orgOrder":0,"company":"MediPharm Labs","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Cannabigerol","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"MediPharm Labs","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Liquid","sponsorNew":"MediPharm Labs \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"MediPharm Labs \/ Not Applicable"},{"orgOrder":0,"company":"Avicanna","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Small molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Cannabidiol","moa":"CB1 receptor","graph1":"Neurology","graph2":"Approved","graph3":"Avicanna","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Avicanna \/ Undisclosed","highestDevelopmentStatusID":"12","companyTruncated":"Avicanna \/ Undisclosed"},{"orgOrder":0,"company":"MediPharm Labs","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"CB receptor","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"MediPharm Labs","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"MediPharm Labs \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"MediPharm Labs \/ Not Applicable"},{"orgOrder":0,"company":"Avicanna","sponsor":"Applied Research Centre at Langara College","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Small molecule","year":"2023","type":"Collaboration","leadProduct":"Cannabidiol","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Avicanna","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Avicanna \/ Applied Research Centre at Langara College","highestDevelopmentStatusID":"12","companyTruncated":"Avicanna \/ Applied Research Centre at Langara College"},{"orgOrder":0,"company":"Avicanna","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Small molecule","year":"2023","type":"Private Placement","leadProduct":"Cannabidiol","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Avicanna","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Avicanna \/ Undisclosed","highestDevelopmentStatusID":"12","companyTruncated":"Avicanna \/ Undisclosed"},{"orgOrder":0,"company":"Avicanna","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Small molecule","year":"2023","type":"Private Placement","leadProduct":"Cannabidiol","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Avicanna","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Avicanna \/ Undisclosed","highestDevelopmentStatusID":"12","companyTruncated":"Avicanna \/ Undisclosed"}]

Find Clinical Drug Pipeline Developments & Deals for Cannabigerol

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : The company will use the proceeds for developing its proprietary formulations and pharmaceutical pipeline including, RHO Phyto having diverse range of proprietary formulations including oral, sublingual, topical, and transdermal deliveries with varying r...

                          Brand Name : RHO Phyto

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          December 04, 2023

                          Lead Product(s) : Cannabidiol,Cannabigerol,Tetrahydrocannabinol

                          Therapeutic Area : Neurology

                          Highest Development Status : Preclinical

                          Sponsor : Undisclosed

                          Deal Size : $0.8 million

                          Deal Type : Private Placement

                          blank

                          02

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : The company will use the proceeds for developing its proprietary formulations and pharmaceutical pipeline including, RHO Phyto having diverse range of proprietary formulations including oral, sublingual, topical, and transdermal deliveries with varying r...

                          Brand Name : RHO Phyto

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          August 02, 2023

                          Lead Product(s) : Cannabidiol,Cannabigerol,Tetrahydrocannabinol

                          Therapeutic Area : Neurology

                          Highest Development Status : Preclinical

                          Sponsor : Undisclosed

                          Deal Size : $1.4 million

                          Deal Type : Private Placement

                          blank

                          03

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : The collaboration aims to focus on Avicanna’s proprietary formulations and pharmaceutical pipeline including, RHO Phyto having diverse range of proprietary formulations including oral, sublingual, topical, and transdermal deliveries with varying ratios...

                          Brand Name : RHO Phyto

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          June 13, 2023

                          Lead Product(s) : Cannabidiol,Cannabigerol,Tetrahydrocannabinol

                          Therapeutic Area : Neurology

                          Highest Development Status : Preclinical

                          Sponsor : Applied Research Centre at Langara College

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          04

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : Through the license and supply agreement, the South American pharmaceutical company will license Avicanna’s intellectual property and supply finished pharmaceutical products starting initially with its proprietary 10% cannabidiol oral preparation, mark...

                          Brand Name : Rho Phyto

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          April 13, 2022

                          Lead Product(s) : Cannabidiol,Tetrahydrocannabinol,Cannabigerol

                          Therapeutic Area : Neurology

                          Highest Development Status : Approved

                          Sponsor : Undisclosed

                          Deal Size : $1.0 million

                          Deal Type : Licensing Agreement

                          blank

                          05

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : New CBG products include Advanced Formula, which is a CBG:CBD 1:2 oil, and Northbound, which is a high CBG vape cartridge with CBD inspired by The White and Appalachia strains.

                          Brand Name : CBG:CBD

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          April 05, 2022

                          Lead Product(s) : Cannabigerol,Cannabidiol

                          Therapeutic Area : Neurology

                          Highest Development Status : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          06

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : Naturally derived oil and inhalable cannabigerol (cannabinoid) products added to MediPharm's wellness portfolio – the benefits of CBG without the effects of THC.

                          Brand Name : Undisclosed

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          April 05, 2022

                          Lead Product(s) : Cannabidiol,Cannabigerol

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          07

                          Oregon State University

                          Country arrow
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Oregon State University

                          Country arrow
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : According to the research by Oregon state university Hemp Comound, Cannabigerolic Acid has a good safety profile in humans and are effective against variants of SARS-CoV-2 including variant.

                          Brand Name : Undisclosed

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          January 10, 2022

                          Lead Product(s) : Cannabigerol

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Preclinical

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          08

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : HUM-234 was shown to prevent weight gain in mice fed a high fat diet, and importantly abrogated the development of fatty liver (steatosis), a condition clinically associated with multiple metabolic disorders, including diabetes and obesity and a precurso...

                          Brand Name : HUM-234

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          October 26, 2021

                          Lead Product(s) : Cannabigerol

                          Therapeutic Area : Neurology

                          Highest Development Status : Preclinical

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          09

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : The programs include in-vitro study of thin film delivery of cannabigerol and quercetin for potential anti-bacterial and anti-viral treatments as well as development of point-of-care sensor-film.

                          Brand Name : Undisclosed

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          March 03, 2020

                          Lead Product(s) : Cannabigerol

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Preclinical

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank